AHA can confirm that Eli Lilly has taken the extraordinary action of denying 340B discounts. Congress should immediately use its oversight authority and demand HHS take a position on drug companies’ attempts to hijack the 340B program through burdensome claims-data demands.
340B Drug Pricing Program
Cookeville Regional Medical Center (CRMC) is an independent, city-owned, not-for-profit, 309-bed regional referral medical center serving more than 350,000 residents across 14 counties.
Eli Lilly said June 1 it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation requirements by next week.
Eli Lilly Moves to Deny 340B Pricing Over Data Requirements; AHA Urges Federal Action
Eli Lilly will soon take the extraordinary step of denying 340B discounts under its unlawful claims data policy. This decision will undoubtedly harm America’s most vulnerable patients and communities, forcing hospitals to divert resources away from care and towards onerous and expensive…
Memo provides details of new CVS 340B contract pharmacy amendment — please share the memo with your legal team
The 4th U.S. Circuit Court of AppealsMay 28 agreed to rehear challenges to 340B contract pharmacy laws from West Virginia and Maryland.
DEADLINE EXTENDED: Complete 340B survey by June 5.
REMINDER: AHA seeks hospital input on scope of drug company 340B data policy compliance by May 26 deadline.
The Wall Street Journal today published a letter to the editor from AHA General Counsel Chad Golder responding to a May 7 editorial criticizing the 340B Drug Pricing Program. The letter states: